Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Stroke After Aortic Valve Surgery
Messé, Steven R. , Acker, Michael A., Fanning, Molly, Giovannetti, Tania , Ratcliffe, Sarah J. , Bilello, Michel , Szeto, Wilson Y. , Bavaria, Joseph E. , Hargrove, W. Clark , Mohler, Emile R., Floyd, Thomas F. , include, The Determining Neurologic Outcomes from Valve Operations (DeNOVO) investigators, Giovanetti, Tania, Matthai, William , Morris, Rohinton J., Pochettino, Alberto , Price, Catherine C. , Selnes, Ola A., Woo, Y. Joseph , Augostides, John G., Cheung, Albert T., Hanson, C. William , Kukafka, Jeremy D., Levy, Warren J., Mickler, Thomas, Milas, Bonnie L., Savino, Joseph S., Vernick, William J., Weiss, Stuart J., Kasner, Scott Eric , include, The Determining Neurologic Outcomes from Valve Operations (DeNOVO) investigators, Desai, Nimesh D. , Horák, Jiří , Kohl, Benjamin

Mayo Clinic

Circulation | April 2, 2014 | Volume: 129 | Issue: 22 | Pages: 2253-2261

10.1161/circulationaha.113.005084 | PMID 24690611 Get It

Background— The incidence and impact of clinical stroke and silent radiographic cerebral infarction complicating open surgical aortic valve replacement (AVR) are poorly characterized. Methods and Results— We performed a prospective cohort study of subjects ≥65 years of age who were undergoing AVR for calcific aortic stenosis. Subjects were evaluated by neurologists preoperatively and postoperatively and underwent postoperative magnetic resonance imaging. Over a 4-year period, 196 subjects were enrolled at 2 sites (mean age, 75.8±6.2 years; 36% women; 6% nonwhite). Clinical strokes were detected in 17%, transient ischemic attack in 2%, and in-hospital mortality was 5%. The frequency of stroke in the Society for Thoracic Surgery database in this cohort was 7%. Most strokes were mild; the median National Institutes of Health Stroke Scale was 3 (interquartile range, 1–9). Clinical stroke was associated with increased length of stay (median, 12 versus 10 days; P =0.02). Moderate or severe stroke (National Institutes of Health Stroke Scale ≥10) occurred in 8 (4%) and was strongly associated with in-hospital mortality (38% versus 4%; P =0.005). Of the 109 stroke-free subjects with postoperative magnetic resonance imaging, silent infarct was identified in 59 (54%). Silent infarct was not associated with in-hospital mortality or increased length of stay. Conclusions— Clinical stroke after AVR was more common than reported previously, more than double for this same cohort in the Society for Thoracic Surgery database, and silent cerebral infarctions were detected in more than half of the patients undergoing AVR. Clinical stroke complicating AVR is associated with increased length of stay and mortality.
Identifying gender differences in reported occupational information from three US population-based case–control studies
Locke, Sarah J. , Colt, Joanne S., Stewart, Patricia A. , Armenti, Karla , Baris, Dalsu , Blair, Aaron, Chow, Wong‐Ho , Davis, Faith G., Roos, Anneclaire J. De , Hartge, Patricia, Johnson, Alison , Purdue, Mark P. , Rothman, Nathaniel , Schwartz, Kendra , Severson, Richard K., Friesen, Melissa C. , Cerhan, James R. , Cozen, Wendy , Karagas, Margaret Rita , Rothman, Nathaniel , Schwenn, Molly R. , Silverman, Debra T. , De Roos, Anneclaire J

Mayo Clinic

Occupational and Environmental Medicine | March 28, 2014 | Volume: 71 | Issue: 12 | Pages: 855-864

10.1136/oemed-2013-101801 | PMID 24683012 Get It

Objectives Growing evidence suggests that gender-blind assessment of exposure may introduce exposure misclassification, but few studies have characterised gender differences across occupations and industries. We pooled control responses to job-specific, industry-specific and exposure-specific questionnaires (modules) that asked detailed questions about work activities from three US population-based case–control studies to examine gender differences in work tasks and their frequencies. Methods We calculated the ratio of female-to-male controls that completed each module. For four job modules (assembly worker, machinist, health professional, janitor/cleaner) and for subgroups of jobs that completed those modules, we evaluated gender differences in task prevalence and frequency using χ2 and Mann–Whitney U tests, respectively. Results The 1360 female and 2245 male controls reported 6033 and 12 083 jobs, respectively. Gender differences in female:male module completion ratios were observed for 39 of 45 modules completed by ≥20 controls. Gender differences in task prevalence varied in direction and magnitude. For example, female janitors were significantly more likely to polish furniture (79% vs 44%), while male janitors were more likely to strip floors (73% vs 50%). Women usually reported more time spent on tasks than men. For example, the median hours per week spent degreasing for production workers in product manufacturing industries was 6.3 for women and 3.0 for men. Conclusions Observed gender differences may reflect actual differences in tasks performed or differences in recall, reporting or perception, all of which contribute to exposure misclassification and impact relative risk estimates. Our findings reinforce the need to capture subject-specific information on work tasks.
A phase I trial of MK‐2206 in children with refractory malignancies: A Children's Oncology Group study
Fouladi, Maryam , Perentesis, John P. , Phillips, Christine L. , Leary, Sarah , McGovern, Renee M., Ingle, Ashish M., Ahern, Charlotte H., Ames, Matthew M. , Houghton, Peter J. , Doyle, L. Austin, Weigel, Brenda J. , Blaney, Susan M. , Reid, Joel M. , Leary, Sarah

Mayo Clinic

Pediatric Blood & Cancer | March 25, 2014 | Volume: 61 | Issue: 7 | Pages: 1246-1251

10.1002/pbc.25023 | PMID 24664955 Get It

BackgroundWe report results of a phase I trial designed to estimate the maximum tolerated dose (MTD), describe dose‐limiting toxicities (DLT), and characterize the pharmacokinetic profile of MK‐2206, an AKT inhibitor, in children with refractory or recurrent malignancies.ProcedureMK‐2206 was administered either every other day (Schedule 1), or once a week (Schedule 2) in a 28‐day cycle. Dose escalations in increments of ∼30% were independently made in each part using the rolling‐six design. Serial pharmacokinetic (PK) studies were obtained. Biological studies include analysis of PI3K/PTEN/AKT‐cell signaling pathway in pre and post‐therapy in PBMC and in tumors at diagnosis or recurrence.ResultsFifty patients (26 males, median age 12.6 years [range, 3.1–21.9]) with malignant glioma (16), ependymoma (4), hepatocellular carcinoma (3), gliomatosis cereberi (2), or other tumors (22) were enrolled; 40 were fully evaluable for toxicity (Schedule 1, n = 23; Schedule 2, n = 17). Schedule 1 DLTs included: grade 3 dehydration in 1/6 patients at 28 mg/m2; grade 4 hyperglycemia and neutropenia in 1/6 patients at 45 mg/m2; and grade 3 rash in 3/6 patients at dose level 4 (58 mg/m2). Schedule 2 DLTs included: grade 3 alkaline phosphatase in 1/6 patients at 90 mg/m2; grade 3 rash in 1/6 patients at 120 mg/m2; and grade 3 rash in 2/6 patients at 155 mg/m2.ConclusionsThe recommended pediatric phase 2 dose of MK‐2206 is 45 mg/m2/dose every other day or 120 mg/m2/dose weekly. PK appeared linear over the dose range studied. Pediatr Blood Cancer 2014;61:1246–1251. © 2014 Wiley Periodicals, Inc.
Infection and Inflammation Leading to Clozapine Toxicity and Intensive Care
Leung, Jonathan G. , Nelson, Sarah , Takala, Christopher R., Gören, Jessica L. , Leung, Jonathan G

Mayo Clinic

Annals of Pharmacotherapy | March 11, 2014 | Volume: 48 | Issue: 6 | Pages: 801-805

10.1177/1060028014526701 | PMID 24619948 Get It

Objective: To describe 3 cases of clozapine toxicity associated with infectious and/or inflammatory processes. Case Summaries: Three patients stable on clozapine therapy prior to a medical hospital admission developed clozapine toxicity. It was suspected that an acute infectious and/or inflammatory process in each patient was related to abrupt mental status changes, onset of sialorrhea, myoclonus, and/or need for ventilatory support. Investigations of altered mental status did not reveal alternative causes and presentations were not consistent with neuroleptic malignant syndrome, other acute neurologic complications, or psychiatric decompensation. All patients improved after clozapine dose reductions allowing for transfer from intensive care units. Using the Naranjo ADR Probability Scale for each case, a probable relation between clozapine toxicity and the infectious and/or inflammatory process was determined. Discussion: Clozapine toxicity may manifest with multiple symptoms, including sedation, sialorrhea, and hypotension. In addition to overdose and drug interactions; infection and/or inflammation may precipitate clozapine toxicity. This may be related to cytokine-mediated inhibition of cytochrome P450 1A2. The likelihood of toxicity via this mechanism has not been well characterized, thus careful monitoring is required for medically ill patients receiving clozapine. Clozapine is extensively bound to the acute phase reactant, α-1 acid glycoprotein, which may unpredictably protect against clinical toxicity. C-reactive protein has also been investigated to relate clozapine toxicity to infection and/or inflammation. Conclusion: Clozapine toxicity developed in 3 patients admitted to a medical setting suspected to be related to infection and/or inflammation. Clinicians should be aware of this potential adverse drug event with clozapine.
Associations Among Fluid Intake, Cognitive Function, and Length of Stay in Psychogeriatric Inpatients
Archer, Sarah J., Barna, Amy E., Holper, Roxanna M., Forsyth, Diane McNally, Ellenbecker, Susan M., Smith, Linda K., Clobes, Jane E., Malone, Chris, Meiers, Sonja J. , Malone, Christopher B., Lapid, Maria I.

Mayo Clinic

Perspectives in Psychiatric Care | March 8, 2014 | Volume: 51 | Issue: 1 | Pages: 52-56

10.1111/ppc.12065 | PMID 24605762 Get It

BIMA V3: an aligner customized for mate pair library sequencing
Drucker, Travis, Johnson, Sarah H. , Cradic, Kendall W, Therneau, Terry M. , Vasmatzis, George , Drucker, Travis M, Murphy, Stephen J.

Mayo Clinic

Bioinformatics | February 14, 2014 | Volume: 30 | Issue: 11 | Pages: 1627-1629

10.1093/bioinformatics/btu078 | PMID 24526710 Get It

Abstract Summary: Mate pair library sequencing is an effective and economical method for detecting genomic structural variants and chromosomal abnormalities. Unfortunately, the mapping and alignment of mate-pair read pairs to a reference genome is a challenging and time-consuming process for most next-generation sequencing alignment programs. Large insert sizes, introduction of library preparation protocol artifacts (biotin junction reads, paired-end read contamination, chimeras, etc.) and presence of structural variant breakpoints within reads increase mapping and alignment complexity. We describe an algorithm that is up to 20 times faster and 25% more accurate than popular next-generation sequencing alignment programs when processing mate pair sequencing. Availability: http://bioinformaticstools.mayo.edu/research/bima/ Contact: vasm@mayo.edu or vasmatzis.george@mayo.edu Supplementary Information: Supplementary data are available at Bioinformatics online.
How common are myeloproliferative neoplasms? A systematic review and meta‐analysis
Titmarsh, Glen J., Duncombe, Andrew , O’Rorke, Michael , Vocht, Frank de , Horan, Sarah, Fritschi, Lin , Clarke, Mike, Anderson, Lesley , McMullin, Mary Frances , Mesa, Ruben A. , Clarke, Mike, Anderson, Lesley A , Fritschi, Lin

Mayo Clinic

American Journal of Hematology | February 12, 2014 | Volume: 89 | Issue: 6 | Pages: 581-587

10.1002/ajh.23690 | PMID 24971434 Get It

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythemia (ET), and primary(idiopathic) myelofibrosis (PMF). In this systematic review, we provide a comprehensive report on the incidence and prevalence of MPNs across the globe. Electronic databases (PubMed, EMBASE, MEDLINE, and Web of Science) were searched from their inception to August 2012 for articles reporting MPN incidence or prevalence rates. A random effects meta‐analysis was undertaken to produce combined incidence rates for PV, ET, and PMF. Both heterogeneity and small study bias were assessed. Thirty‐four studies were included. Reported annual incidence rates ranged from 0.01 to 2.61, 0.21 to 2.27, and 0.22 to 0.99 per 100,000 for PV, ET, and PMF, respectively. The combined annual incidence rates for PV, ET, and PMF were 0.84, 1.03, and 0.47 per 100,000. There was high heterogeneity across disease entities (I2 97.1–99.8%) and evidence of publication bias for ET and PMF (Egger test, P = 0.007 and P ≤ 0.001, respectively).The pooled incidence reflects the rarity of MPNs. The calculated pooled incidence rates do not reflect MPN incidence across the globe due to the high unexplained heterogeneity. Improved, widespread registration of MPNs would provide better information for global comparison of the incidence and prevalence of MPNs. Am. J. Hematol. 89:581–587, 2014. © 2014 Wiley Periodicals, Inc.
Occlusion for stimulus deprivation amblyopia
Antonio‐Santos, Aileen A. , Vedula, Satyanarayana S, Powell, Christine, Hatt, Sarah R.

Mayo Clinic

Cochrane Database of Systematic Reviews | February 6, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/14651858.cd005136.pub3 | PMID 24504975 Get It

Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
Weroha, S. John , Becker, Marc A., Enderica-Gonzalez, Sergio, Harrington, Sean C., Oberg, Ann L. , Maurer, Matthew J. , AlHilli, Mariam , Butler, Kristina , McKinstry, Sarah, Fink, Stephanie, Jenkins, Robert B. , Hou, Xiaonan , Kalli, Kimberly R., Goodman, Karin M., Hartmann, Lynn C. , Haluska, Paul , Perkins, Sarah E. , Sarkaria, Jann N. , Karlan, Beth Y. , Kumar, Amanika , Kaufmann, Scott H. , Maurer, Matthew

Mayo Clinic

Clinical Cancer Research | January 8, 2014 | Volume: 20 | Issue: 5 | Pages: 1288-1297

10.1158/1078-0432.ccr-13-2611 | PMID 24398046 Get It

Abstract Purpose: Ovarian cancer has a high recurrence and mortality rate. A barrier to improved outcomes includes a lack of accurate models for preclinical testing of novel therapeutics. Experimental Design: Clinically relevant, patient-derived tumorgraft models were generated from sequential patients and the first 168 engrafted models are described. Fresh ovarian, primary peritoneal, and fallopian tube carcinomas were collected at the time of debulking surgery and injected intraperitoneally into severe combined immunodeficient mice. Results: Tumorgrafts demonstrated a 74% engraftment rate with microscopic fidelity of primary tumor characteristics. Low-passage tumorgrafts also showed comparable genomic aberrations with the corresponding primary tumor and exhibit gene set enrichment of multiple ovarian cancer molecular subtypes, similar to patient tumors. Importantly, each of these tumorgraft models is annotated with clinical data and for those that have been tested, response to platinum chemotherapy correlates with the source patient. Conclusions: Presented herein is the largest known living tumor bank of patient-derived, ovarian tumorgraft models that can be applied to the development of personalized cancer treatment. Clin Cancer Res; 20(5); 1288–97. ©2014 AACR.